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Abstract
Background: Recently, the tuberculosis (TB) Task Force Impact Measurement acknowledged the need to review the
assumptions underlying the TB mortality estimates published annually by the World Health Organization (WHO). TB
mortality is indirectly measured by multiplying estimated TB incidence with estimated case fatality ratio (CFR). We
conducted a meta-analysis to estimate the TB case fatality ratio in TB patients having initiated TB treatment.
Methods: We searched for eligible studies in the PubMed and Embase databases through March 4
th 2011 and by reference
listing of relevant review articles. Main analyses included the estimation of the pooled percentages of: a) TB patients dying
due to TB after having initiated TB treatment and b) TB patients dying during TB treatment. Pooled percentages were
estimated using random effects regression models on the combined patient population from all studies.
Main Results: We identified 69 relevant studies of which 22 provided data on mortality due to TB and 59 provided data on
mortality during TB treatment. Among HIV infected persons the pooled percentage of TB patients dying due to TB was 9.2%
(95% Confidence Interval (CI): 3.7%–14.7%) and among HIV uninfected persons 3.0% (95% CI: 21.2%–7.4%) based on the
results of eight and three studies respectively providing data for this analyses. The pooled percentage of TB patients dying
during TB treatment was 18.8% (95% CI: 14.8%–22.8%) among HIV infected patients and 3.5% (95% CI: 2.0%–4.92%) among
HIV uninfected patients based on the results of 27 and 19 studies respectively.
Conclusion: The results of the literature review are useful in generating prior distributions of CFR in countries with vital
registration systems and have contributed towards revised estimates of TB mortality This literature review did not provide
us with all data needed for a valid estimation of TB CFR in TB patients initiating TB treatment.
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Introduction
Each year, the World Health Organization (WHO) publishes
country-specific estimates of tuberculosis (TB) incidence, TB
prevalence and TB mortality [1]. In countries without adequate
data from national vital registration systems, TB deaths are
indirectly estimated by multiplying estimated TB incidence with
an estimate of the case-fatality ratio (CFR), accounting for
uncertainty in incidence and CFR [2]. Such indirect TB mortality
estimates heavily depend on the reliability of underlying estimates
of incidence and CFR [3]. The CFR is defined as the probability
of dying from a disease before recovering or dying of something
else [4]. The TB CFR is defined as the proportion of TB patients
dying due to TB [5]. In the past, the TB CFR estimates used by
WHO and reported in several publications and journals [3,5–7]
were based on literature searches assessing mortality during TB
treatment; risk of TB relapse and late complications; autopsy series
for the cause of death in patients with TB according to human
immunodeficiency virus (HIV) status, smear status and treatment
regimen. The results from the literature searches, along with
treatment results reported to the WHO and country-specific
estimates calculated for 1997, were used to estimate CFRs for
patients with TB. The resulting CFR for TB patients varied
between countries [5]. Other non systematic literature reviews
have also reported CFRs in TB patients [8,9]. Mukadi et al. [8]
provided a limited description of the review methodology,
however, it remained unclear how results of individual studies
contributed to the selection of CFR values for TB mortality
estimation purposes. Maher et al. defined TB CFR as the
proportion of TB patients that died within a specified time,
without any specification of cause of death [9].
In 2008 it was acknowledged by the Task Force Impact
Measurement that the TB CFR needed to be reviewed by a
combination of methodologies that included assessment of
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registration data in countries that have ‘reliable’ data from these
two sources and using data from the literature [10]. To meet this
need we have conducted a systematic literature review including a
meta-analysis to estimate the TB CFR in TB patients initiating TB
treatment, by identifying published studies in which information
on TB mortality in a cohort of TB patients receiving TB treatment
is available. By summarizing the results obtained from the
identified studies we aim to contribute to a revision of the CFR
for TB patients initiating TB treatment currently being used by
WHO when estimating TB mortality [6,11]. The methodology
and results of the estimates for the duration and CFR in untreated
TB patients are reported elsewhere [12].
Methods
A protocol was developed in advance of conducting the
systematic review.
Search strategy
To identify studies reporting TB CFR in TB patients initiating
TB treatment or information that can be used to calculate the
CFR, we searched the PubMed and Embase databases through
March 4
th 2011. We combined the search strategy of the free text
terms ‘case fatality’ AND ‘tuberculosis’ with the ‘OR’ operator
including the exploded MESH headings ‘mortality’ AND
‘tuberculosis’ AND cause of death’. The search was limited to
humans, and we excluded from the search strategy the publication
type ‘letter’. We further performed reference listing of relevant
review articles that were identified in the search [5,8,11,13,14] and
review articles not identified in the search but which were known
by the authors [3,9,15].
Eligibility criteria and study selection
Eligible studies included cohort studies, clinical trials and case
control studies. Case control studies were only included if the
manuscript reported data on mortality for the group of patients
starting TB treatment in addition to conducting the case control
analyses. The population studied included pulmonary and
extrapulmonary TB patients of both sexes and all ages who
initiated TB treatment. The studies needed to report on TB
treatment and mortality due to TB or mortality during TB treatment.
We excluded studies conducted in limited populations as they were
less likely to be representative of the average TB patient, for
example studies of patients with liver cirrhosis [16], health care
workers [17,18] or patients in intensive care units [19].
Furthermore, we excluded non-English articles and, in an attempt
to minimize bias, we also decided a posteriori to exclude one
article in which authors stated that their recorded mortality data
were clearly inaccurate [20]. Identified studies were reviewed for
eligibility by one author (MS) based on title and abstract. The full
text article was obtained for those articles of which the abstract
reported data on case fatality ratio, prospective or retrospective
studies in a TB cohort with report of mortality data, cohort study
with measurement of incident TB and mortality. For reference
listing of the eight review articles [3,5,8,9,11,13–15] we decided to
retrieve the full text of the article if the citation in the review article
reported CFR or if the title was indicative of measurement of
mortality in treated TB patients.
Data extraction
One reviewer (MS) extracted data from all eligible studies and a
second reviewer (MvdW) independently extracted data from a
random subset of 20% of the articles. No major discrepancies were
identified in the most important variables. Data extraction
included: information on first author; year of publication; study
design; country in which the study was performed; setting;
coverage; study period; age of cohort initiating TB treatment,
type of TB patient (e.g. new, re-treated); TB form (pulmonary,
extra pulmonary); type of treatment (standardized versus non-
standardized regimen) and duration, Human Immunodeficiency
Virus (HIV)- status; multi drug resistance (MDR) status; smear
status; whether TB had been registered as cause of death or
whether mortality during TB treatment was reported; number of
TB patients receiving TB treatment and number of TB patients
died.
Although we originally planned to extract data on follow up
time, number of patients lost to follow up, use of cotrimoxazole
prophylaxis, co-morbidities and use of anti-retroviral therapy,
these data appeared to be limited and consequently could only be
partly considered in the description of the retrieved studies.
We classified TB treatment as standardized if 1) the described
treatment regimen was in line with WHO recommendations as
described in guidelines published in 1997 [21] or 2003 [22]; 2) the
treatment regimen was described as following the national/
governmental guidelines; 3) the treatment regimen was described
as direct observed treatment strategy (DOTS); 4) the treatment
regimen was described as ‘standard’. We classified TB treatment
as non-standardized if 1) TB treatment was described as
‘individual tailored regimen’; 2) the treatment regimen was
described as ‘according to non-governmental organization’
(NGO); 3) the treatment regimen was described as ‘unsupervised
ambulatory’. If the treatment regimen was described as unknown,
this was categorized as unknown treatment regimen. These studies
were considered as having received non-standardized TB
treatment. In two studies part of the cohort received standard
TB treatment and part non standard [23,24]. Although we
originally planned to present the results differently for those
patients receiving standardized and non-standardized treatment
the numbers were too small. To assess the robustness of our results
we conducted a sensitivity analyses by excluding studies in which
treatment was categorized as non-standardized.
Operationalisation of outcome measures
The primary outcome measure was the percentage of TB
patients initiating TB treatment that died due to TB within a
specific time period. This was defined as TB CFR and was
calculated by dividing the number of TB patients dying due to TB
by the total number of TB patients in the cohort initiating TB
treatment, multiplied by 100. Studies having reported the
registration of cause of death and having reported TB as either
‘primary cause of death’, ‘contributory cause of death’, ‘immediate
cause of death’ or ‘related to TB’ were included in this analysis.
The secondary outcome measure was the percentage of TB
patients dying during TB treatment, irrespective of cause of death.
Quality assessment
No quality assessment of studies was done. Existing quality
assessment tools were judged not to be relevant for the quality
assessment of the type of studies included and the outcome
measure of interest. Furthermore, it was expected that the use of a
quality assessment tool would not result in a large variability in
quality assessment scores of the individual studies.
Synthesis of results
For our main analyses we have calculated the pooled percentage
of deaths due to TB (primary outcome measure) and the pooled
percentage of overall deaths during TB treatment (secondary
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pooled percentages of death across all studies, accounting for the
clustering effect (at the level of the study), and the standard error
(s.e.) of the point prevalence, we used random effect regression
models. Models were fitted using individual patients as the unit of
analysis, achieved after appropriate expansion and pooling of the
aggregated counts of patients who died and survived in each study.
We present the estimated pooled prevalence with the 95%
confidence interval (CI).
Originally we planned to conduct subgroup analyses for new
and retreated TB patients. However, the studies did not always
make this distinction and/or the number of studies in each
category was limited. Therefore, we only present data for new and
re-treated TB patients combined. We also planned to conduct
separate analyses for different age categories, but the studies did
not provide separate results for different age categegories.
Information for the following subgroups: HIV status, smear status;
multi-drug-resistance (MDR) TB and combinations within these
categories are presented when available.
For our secondary analyses we included studies providing
information on both the total number of TB patients dying during
TB treatment and the number of TB patients dying during TB
treatment due to TB, to estimate the pooled percentage of total
deaths during TB treatment that were attributed to TB. The
pooled percentage of overall mortality within four years after TB
treatment initiation was also assessed. Analyses were done with the
statistical software STATA 11.0.
Results
Identified studies
Seven - hundred-fifty-four potentially relevant studies were
identified from the PubMed and Embase databases of which 46
were eligible for our review. Reference listing of relevant review
articles identified 24 additional articles See figure 1 for the flow
diagram for study selection.
Description of characteristics included studies
The search identified 70 relevant articles of which two articles
referred to the same study but were included separately in the
analyses as one article provided data on mortality due to TB [25]
and the other article provided data on mortality during and after
TB treatment [26]. Twenty-eight of the 69 different studies were
prospective cohort studies [23,25–52]; 31 retrospective cohort
studies [24,53–82], five retrospective record reviews [83–87]; four
trials [88–91] and one case control study [92]. (Table S1)
Almost half of the studies (46%, 32/69) were performed in
Africa [27–35,37–40,42,48–50,52,58,61–63,69,74,81,82,86–91]
followed by 18 studies in Asia [23,36,43–47,60,64,65,70,71,73,
75,76,78–80]; nine studies in America [24–26,54,57,72,77,83–85]
Figure 1. Flow diagram of papers accepted and rejected during selection procedure.
doi:10.1371/journal.pone.0020755.g001
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study from Australia [56]. These numbers include the study results
in six different countries as reported by Espinal et al. [73] and the
study of Ciglinecki et al. [89] reporting study results of two different
African countries.
The geographical coverage of the study population was in 26
studies one city including its surrounding area’s [28–32,35,37–
39,45,47,48,50,54,55,57,65,67,73,76,85–89,91] in 25 studies one
specific district or region in the country [25–27,33,34,42,
43,46,49,53,58–63,69–74,80,82,90,92], 10 national studies [36,41,
51,64,66,68,77,79,81,84] although one [51] reported that national
coverage was not 100%; 8 were done in states or provinces
[23,24,40,52,56,75,78,83] and one study was performed in
hospitals covering 80% of the population [44].
Eighteen studies did not report on age of the TB patients. In the
majority of the included studies that reported on age of the TB
patients initiating TB treatment TB patients were between 20 and
40 years old. Hussey et al. [86] included children (median age 10.5
months) with childhood miliary tuberculosis while the studies of
Fielder et al. [57]; Shen et al. [76] and Sakurai et al. [47] included a
relative large proportion of individuals aged older than 50 years.
(Table S1)
Only 5 of the 32 studies reporting on mortality in TB patients
with HIV specifically reported the use of prophylaxis in HIV
infected TB patients [23,54,82,90,91]. while one study reported
that no prophylaxis was used [89]. Use of antiretrovirals in HIV
infected TB patients was reported in 5 studies (16%) [23,53–55,91]
of which 3 were conducted after 1996, when highly active
antiretroviral therapy (HAART) [23,55,91] became available.
Only the study of Abdool-Karim et al. [91] reported that 100% of
the HIV infected TB patients received antiretroviral treatment;
while in the study of Cain et al. [23] and Dean et al. [55]
respectively 44% and 46% of HIV infected TB patients received
ARTs.
Only a few studies included detailed information on the severity
of HIV disease by for example providing information on CD4 cell
count [30,32,53,54,90,91] or HIV stages [32,38,50,54,89,91]. In
the majority (83%) of the studies reporting on CD4 cell count
either the median CD4 cell count was ,200 cells/mm
3 [91,93] or
at least 50% of the cohort had CD4 cell counts less than ,200
cells/mm
3 [32,53,90]. In the three studies not reporting CD4 cell
count but only reporting on HIV stage according to WHOs
clinical AIDS definition [38,50,89] the percentage of HIV positive
TB patients defined as having AIDS varied from 61.8% [38] to
76% [50]. Comorbidities were reported in less than one third
(27%) of the studies reporting on mortality in HIV positive TB
patients [23,28,29,37–39,50,55,90]. Due to lack of detailed
information regarding use of antiretrovirals, severity of HIV
disease and comorbidities we did not further include these
parameters in any subgroup analyses.
Primary outcome measure: Mortality due to TB
Cause of death was reported in 22 studies [23–25,30,44,47,
50,53,54,56,57,59,66–68,75,76,79,83–85,90]. Use of verbal au-
topsy data additional to clinical information was reported by two
studies [23,90]. Twenty studies established cause of death using
clinical records, review of files and/or death certificates. In these
studies, TB was either reported as ‘primary cause of death’
[25,54,56,57,84] or as ‘cause of death’ [44,47,66–68,75,76]; while
studies also reported TB as ‘contributory cause of death’
[30,56,57,76,84,85], attributed to TB [79], ‘immediate cause of
death’ [50] or ‘related to TB’ [24,53,59,83]. Data of the primary
and contributory cause of death were aggregated per study in
three studies distinguishing between TB as primary and contrib-
utory cause of death [56,57,84]. Three studies did not report on
which was the primary cause of death when TB was recorded as
contributory cause of death. Three studies reported on mortality in
new TB patients [30,44,57]; while only one study [59] provided
mortality data in retreated TB patients and the majority of studies
did not reported separately for new and retreated TB patients.
The pooled TB CFR (percentage death due to TB) in HIV-
uninfected persons was 3.0% (95% CI: 21.3%–7.4.%) and the
pooled TB CFR in HIV infected persons was 9.2% (95% CI:
3.7%–14.7%), based on the results of three and eight studies
respectively that reported on cause of mortality in these groups
(Table 1, Figure 2&3). The percentage deaths due to TB in smear
positives (11.7% 95% CI: 7.4%–15.9%) was higher than in smear
negatives (5.7%, 95% CI: 2.6%–11.1%, irrespective of HIV status,
based on the results of 3 and 2 studies respectively (Table 1). Only
two studies [54,85] provided information on TB as cause of death
for multi drug resistant (MDR) TB patients. The pooled TB CFR
in HIV positive MDR TB patients was 30.9% (95%CI: 21.7%–
40.1%).
Excluding the two studies in HIV infected TB patients in which
treatment was either classified as non-standardized [85] or in
which some patients received non standardized and some
standardized TB treatment [23] only slightly decreased the pooled
CFR from 9.2% to 8.4% (95% 3.0–13.7%). Including only studies
conducted in non-MDR TB patients receiving standardized TB
treatment [30,50,53,83,90] further decreased the CFR to 5.8%
(95% CI: 3.9%–7.8%).
All three studies in HIV uninfected TB patients received
standardized TB treatment, but excluding the study done in HIV
uninfected MDR TB patients [85] resulted in a CFR of 1.6%
(95% CI 20.4%–3.7%). The smear positive TB patients
[25,57,59] all received standardized treatment and did not
specifically report that MDR TB patients were included. In the
sub group analyses of smear negative TB, excluding the study of
Lau et al. [44] in which extra pulmonary TB patients received non
standardized treatment, the CFR based on only 1 study [59] was
2.9% (95% CI: 1.9%–4.0%).
Secondary outcome measure: Mortality during TB
treatment
Mortality during TB treatment was reported in 59 studies
[23,26–43,45,46,48,49,51,52,55–66,68–78,80–83,86–92]. Eight
studies provided mortality data in either retreated [26,33,51,
60,76,91] or relapsed TB patients [27,59] while the majority of the
studies reported mortality data on either only new TB patients or
new and retreated TB patients. In 6 studies, the treatment strategy
was categorized as non-standardized treatment [41,60,65,75,
77,78] including 4 studies in which the treatment strategy was
not specified [41,75,77,78]. The study of Cain et al. [23] described
that the cohort included both persons receiving standardized and
non standardized treatment. These six studies included either only
HIV infected - and/or HIV uninfected TB patients [23,77,78],
MDR TB patients [60], extrapulmonary TB patients [65] or did
not report stratified results [41].
Stratified by HIV status, the pooled percentage of deaths during
TB treatment was 3.5% (95% CI: 2.5%–7.2%) in HIV uninfected
persons and 18.8% (95% CI: 14.8%–22.8%) in HIV infected
persons, based on the results of 19 and 27 individual studies
respectively (Table 1, Figure 4&5). The percentage of deaths in
smear positives was 8.3% (95% CI: 5.9%–10.7%) and 15.2%
(95% CI: 7.5%–22.7%) in smear negatives based on the results of
27 and 13 studies respectively. (Table 1) Excluding the studies with
non standardized TB treatment [23,77,78] resulted in similar
CFRs for HIV uninfected persons (3.3%; 95% CI: 1.7–5.0) as well
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Excluding the three studies conducted in HIV infected TB patients
after 1996 and reporting that at least part of the cohort received
ARVs resulted in a slightly higher CFR (20.4%; 95% CI: 16.2%–
24.6%) but the 95% CIs were overlapping.
Proportion of deaths due to tuberculosis among treated
tuberculosis patients that died during tuberculosis
treatment. Not all deaths occurring during TB treatment have
TB disease as their cause. In our systematic review, 13 studies
provided information on the total number of TB patients dying
during TB treatment as well as the total number of TB patients
dying during TB treatment due to TB (Table S2) [23,30,50,56,
57,59,66,68,75,76,83,85,90]. Using these studies we assessed the
proportion of deaths during TB treatment that were due to TB.
Excluding the study with HIV infected MDR TB patients [85],
the average proportion of HIV infected persons dying during TB
treatment was 18.9% (95% CI: 11.6%–26.2%). In these studies
among HIV infected persons dying during TB treatment only
4.6% (95% CI 3.2%–6.0%) of the deaths were reported to be due to
TB [23,30,50,83,90]. Consequently, based on these results we
estimate that of all HIV infected TB patients dying during TB
treatment around 24% die due to TB. Cause of death in HIV
infected TB patients was assessed by different methods or a
combination of methods, review of clinical data, autopsy results,
death certificates, medical records and interviews with relatives
(Table S2). Other main causes of death as reported in these studies
included Pneumocystis carinii Pneumoniae [83], pneumonia [50,83]
gastro intestinal disease [50,90] wasting syndrome, Kaposi’s
sarcoma [83,90], meningitis [90], central nervous system syn-
drome not caused by infections, (other) opportunistic infections
[83,90], toxic epidermal necrolysis [50] and miscellaneous causes
[83] or unknown cause [50,83,90].
Excluding the study with HIV uninfected MDR TB patients
[85], the average proportion of HIV uninfected TB patients
[30,50] and TB patients in countries of which we assume have a
low HIV prevalence [56,57,59,66,68,75,76,94], dying during TB
treatment was 6.5% (95% CI: 3.0% to 9.9%, while among these
studies 3.4% (95% CI: 1.1% to 5.7%) died during TB treatment
due to TB. Consequently, it seems that of all HIV uninfected
persons dying during TB treatment, about one half die due to
TB.
Information on timing of mortality due to TB was only reported
in six studies [23,50,56,59,83,84] The majority of deaths during
TB treatment that were due to TB appeared to occur in the first
months after TB diagnosis or start of treatment. Small et al. [83]
reported that 75% (6 of 8) of TB patients dying due to TB died
Table 1. Average pooled tuberculosis (TB) Case Fatality Ratio (CFR) (expressed as percentage) estimated from studies that have
registered TB as cause of death * in treated TB patients (primary endpoint) or studies that have reported mortality during TB
treatment { (secondary endpoint).
Primary endpoint Secondary endpoint
CFR (%) (95%
Confidence Interval) 1 References
CFR (%) (95%
Confidence Interval References
Overall 4.2% (2.3%–6.1%)
{ [24,47,56,66–68,75,76,79,84,85] 5.8% (3.1%–8.4%) [41,51,56,58,60,62,63,66,68–70,72,73,75,76,78,80,92]
?
HIV uninfected 3.0% (0.0%–7.4%)
{ [30,50,85] 3.5%% (2.0%–4.9%) [27–30,32,35,37–40,48,49,51,69,74,77,78,87,89]
Smear positive 0.5% (0.0%–2.9%) [30] 1.6% (0.1%–3.2%) [29,30,32,33,38,40,89]
Smear negative – – 7.5% (20.9%–16.0%) [33,40,74]
HIV infected 9.2% (3.7%–14.7%)
{ [23,30,50,53,54,83,85,90] 18.8% (14.8%–22.8%) [23,27–30,32,35,37–
40,48,49,51,55,63,69,74,77,78,82,83,87–91]
Smear positive 4.6% (3.2%–6.1%) [30,90] 15.6% (11.1%–20.2%) [29,30,32,33,38,40,63,74,88–91]
Smear negative – – 37.7% (22.7%–52.7%) [33,40,63]
Smear positive 11.7% (7.4%–15.9%) [25,57,59] 8.3% (5.9%–10.7%) [26,27,31–33,36,38,40,42,43,45,46,52,57–
59,61,63,64,71,74,76,81,89,91,92]
Smear negative 5.7% (2.6%–11.1%)
{ [44,59] 15.2% (7.5%–22.8%) [27,31,33,34,40,42,59,63,68,69,76,81,86]
"
Extra Pulmonary included in overall smear
negative CFR
included in overall smear
negative CFR
18.2% (9.6%–26.7%) [33,42,63,65,68,81,86]
Multi drug resistant TB 21.1% (14.6%–27.5%) [85] 4.7% (0.2%–9.2%) [60,73,76]
{
HIV infected 30.9% (21.7%–40.1%) [54,85]
HIV uninfected 12.8% (2.3%–23.3%) [85]
Smear positives 12.2% (2.2%–22.2%) [26]
*Studies have registered cause of death based on either verbal autopsy additional to clinical information [23,90] or vital registration in which clinical records and/or
death certificates have been reviewed and TB was either reported to be (primary) cause of death [25,54,56,57,84] [44,47,66–68,75,76]; contributory cause of death
[30,56,57,76,84,85]; attributed to TB [79], TB as ‘immediate cause of death’ [50] or death was described as ‘related to TB’. [24,53,59,83];
{Including one study {326/id} reporting treatment outcome data from 6 individual studies in 6 different countries and one study reporting on two separate cohorts in
Zambia and Malawi [89] The individual estimates in these two studies have contributed to the pooled estimates as reported in this table;
1Results of individual studies which have published TB mortality data with different certainties of TB as cause of death [56,57,84] have only been included once in the
overall analyses by calculating the cumulative mortality of both categories of TB as cause of death;
{Including two studies in only MDR TB patients [54,85];
{Including one study in only extra–pulmonary TB cases [44];
?Including one study in only MDR TB patients [60];
"Including seven studies reporting mortality during TB treatment of smear negative pulmonary TB patients [31,34,40,42,63,76,81]; three studies reporting mortality
during TB treatment in both smear negative pulmonary TB and extrapulmonary TB [27,33,59]and three studies reporting mortality during treatment of extra
pulmonary TB patients. [68,69,86].
doi:10.1371/journal.pone.0020755.t001
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that at least 65% of the persons who died due to TB died within
the first 3 months after initiating TB treatment. Walpola et al. [56]
reported that of the 54 TB related deaths that started TB
treatment 43% died within one month and 74% within 3 months
after commencing TB treatment, similar to the study of Xie et al.
Figure 2. Forest plot of 3 studies reporting mortality due to TB as percentage of total number of HIV uninfected persons receiving
TB treatment. (I-squared=78.6%, p=0.009). The Study ID on the Y-axis includes the name of the first author and publication year; for each study
the central square indicates the mortality percentage and the horizontal line denotes the 95% confidence interval (CI) around the mortality
percentage. The size of the square indicates the impact the specific study has on the point estimate of the pooled estimate. The vertical dashed line
indicates the pooled mortality percentage and the outer edges of the diamond represent the 95% confidence interval (CI) around the pooled
estimate; the X-axis indicates the scale of mortality percentage.
doi:10.1371/journal.pone.0020755.g002
Figure 3. Forest plot of 8 studies reporting mortality due to TB as percentage of total number of HIV infected persons receiving TB
treatment. (I-squared=82.1%, p=0.000). The Study ID on the Y-axis includes the name of the first author and publication year; for each study the
central square indicates the mortality percentage and the horizontal line denotes the 95% confidence interval (CI) around the mortality percentage.
The size of the square indicates the impact the specific study has on the point estimate of the pooled estimate. The vertical dashed line indicates the
pooled mortality percentage and the outer edges of the diamond represent the 95% confidence interval (CI) around the pooled estimate; the X-axis
indicates the scale of mortality percentage.
doi:10.1371/journal.pone.0020755.g003
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20755[84] where 67% died within 3 months after initiating TB
treatment. In the study of Cain et al. [23] also 65% of the deaths
of which probability of TB cause of death was probable or high
died within 2 months after initiating TB treatment. Nunn et al. [50]
looked at TB as cause of death within 6 months after initiating 12
month duration treatment. Among HIV infected- and HIV
Figure 4. Forest plot of 19 individual studies reporting mortality during TB treatment as percentage of total number of HIV
uninfected persons receiving TB treatment. (I-squared=88.6%, p=0.000). The Study ID on the Y-axis includes the name of the first author and
publication year; for each study the central square indicates the mortality percentage and the horizontal line denotes the 95% confidence interval (CI)
around the mortality percentage. The size of the square indicates the impact the specific study has on the point estimate of the pooled estimate. The
vertical dashed line indicates the pooled mortality percentage and the outer edges of the diamond represent the 95% confidence interval (CI) around
the pooled estimate; the X-axis indicates the scale of mortality percentage.
doi:10.1371/journal.pone.0020755.g004
Figure 5. Forest plot of 27 individual studies reporting mortality during TB treatment as percentage of total number of HIV infected
persons receiving TB treatment. (I-squared=92.8%, p=0.000). The Study ID on the Y-axis includes the name of the first author and publication
year; for each study the central square indicates the mortality percentage and the horizontal line denotes the 95% confidence interval (CI) around the
mortality percentage. The size of the square indicates the impact the specific study has on the point estimate of the pooled estimate. The vertical
dashed line indicates the pooled mortality percentage and the outer edges of the diamond represent the 95% confidence interval (CI) around the
pooled estimate; the X-axis indicates the scale of mortality percentage.
doi:10.1371/journal.pone.0020755.g005
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within six months of follow up after TB treatment was initiated,
occurred in the first month.
Overall mortality within four years after initiating TB
treatment. Deaths occurring after completion of TB treatment
may also be attributed to TB and therefore be included in the TB
CFR. Fourteen studies reported follow–up data on overall
mortality after the duration of the TB treatment or referred to
other publications of the same study that described this follow
up data [26–29,33,38,43,45,46,48,70,83,87,89] (Table S3). The
average percentage of HIV uninfected persons dying within a
maximum follow up period of four years after initiating TB
treatment was 9.0% (95% CI: range 4.5% to 13.5%) and 41.7%
(95% CI: 30.8% to 52.5%) among HIV infected TB patients. For
this analysis we excluded the study of which follow up period was
unknown [26]. Among HIV uninfected persons an average 46%
(95% CI: 30.7% to 62.2%) of total deaths within maximum four
years of follow up died after TB treatment completion [27–
29,33,38,48,83,87,89]. This indicates that around 54% of all
deaths in HIV uninfected TB patients died during TB treatment.
Among HIV infected persons in the same studies this percentage
was 41.3% (95% CI: 31.2%–51.3%).
It should be noted that of the 14 studies containing data on
mortality during TB treatment and mortality during the follow up
period, only three studies reported mortality data due to TB
[27,45,83]. The percentage of deaths occurring after completion of
TB treatment that could be attributed to TB varied largely from
10% [83] to 80% [45].
Discussion
We have conducted this systematic literature review to estimate
the TB case fatality ratio in TB patients starting TB treatment and
consequently contribute to a revision of the CFR for TB patients
currently used by WHO for estimating TB mortality [3,6,11]. We
found that among HIV infected persons initiating TB treatment
9% (95% CI: 4% to 15%) and among HIV uninfected persons 3%
(95% CI: 21.2% to 7.4%) died due to TB during the follow up
period of the study. Because of different follow up times of the
studies included we were unable to establish the time period to
these percentages. The number of studies specifically reporting on
TB as cause of death was limited therefore we also looked at
studies reporting on overall mortality during TB treatment. We
found that among HIV infected persons starting TB treatment
19% (95% CI: 15%–23%) died during TB treatment and among
HIV uninfected persons this percentage was 4% (95% CI: 2%–
5%).
Previously, WHO has published CFRs which were partly based
on estimations of the percentage of TB patients dying from TB
during TB treatment. The results of our systematic review add
data for the underlying assumptions. We found that of the total
number of deaths during TB treatment, TB had been considered
the cause of, or contributed to, death in 24% of the deaths in HIV
infected persons and in about half of deaths in HIV uninfected TB
persons. During routine TB treatment outcome monitoring,
reported deaths during TB treatment usually do not discriminate
between deaths due to TB and deaths due to other causes.
Therefore, our information may be useful for linking with routine
reporting of deaths during TB treatment and estimate the
percentage of deaths due to TB when overall mortality during
TB treatment is reported.
A few limitations need to be considered. First, the average
proportion of deaths due to TB among all deaths during TB
treatment are based on only five studies in HIV infected - and ten
in HIV uninfected TB patients. In the individual studies this
proportion varied from 16% in the USA in which 41% of the HIV
infected population starting TB treatment died during TB
treatment [83], to 46% in the study of Perriens et al.. [30] in
which 13% died during TB treatment. This wide inter study
variation may be due to variations between settings e.g. as a
consequence of differences in age of the TB population in specific
countries and potential bias and confounding factors. The
percentages are also sensitive to miscoding causes of death.
According to the International Classification of Diseases, 10
th
revision (ICD–10) deaths from TB in individuals infected with
HIV should be classified as HIV deaths [6]. In some countries TB
might be coded as contributory cause of death [2]. Several
definitions were used in the studies. Leroy et al. [53] classified
deaths in people living with HIV and TB as definite TB death in
patients without a history of other AIDS–related disease and
without any other known cause of death. Walpola et al. [56]
reported TB as primary and contributory cause of death but did
not differentiate between HIV infected and HIV uninfected TB
patients. Diagnosing TB as cause of death is known to be
problematic in several settings. Moorman et al. [95] conducted a
study to assess the quality of data of reported deaths from TB in a
rural South African district hospital, and determined the actual
cause of death of patients who died whilst on TB treatment. They
found several reasons for miscoding of TB deaths; e.g. TB was
assumed to be the cause of death if the patient died on the TB
ward. Furthermore, death certificates were inaccurate and often
two illnesses were recorded as the main cause of death. Older
patients over the age of 65 were more likely to have a number of
concomitant diseases that may cause death, and particular care
should be taken in this age group in recording a death as due to
TB. Despite uncertainties in measuring TB mortality, causes of
death as coded in the death certificates are still considered as the
gold standard. By means of adequate training of medical doctors
filling and signing the death certificates and the use of
standardized coding practices, these uncertainties can be mini-
mized. To obtain a more accurate estimate of TB CFR in England
and Wales, Crofts et al. [96] compared mortality ascertained by the
national TB surveillance with record linkage to mortality
information from the National Health Service central register
and death registration from the Office for National Statistics. A
capture recapture methodology was used to estimate unascer-
tained deaths for final calculation of CFR. They not only
quantified the number of deaths missed by the national TB
surveillance, but their findings also showed consistently that half of
deaths among TB patients are due to TB.
The CFRs estimates as published by WHO previously were
based on assumptions regarding the percentage of late deaths from
relapse or post–tuberculous complications and deaths of untreated
TB patients [6,11]. The study of Vijay et al. showed that 66% of
the deaths occurring within 2.5 years after initiating TB treatment
occurred among the defaulters. Of those deaths, 87% were
considered attributable to TB [45]. None of the included studies
showed data on TB mortality in patients who defaulted,
transferred out or were lost to follow up. We only found three
studies [27,45,83] reporting on a wide variation of mortality due to
TB after treatment completion. The limited data on mortality after
TB treatment completion and/or among defaulters and lost to
follow up, prevented us from making firm conclusions about the
percentage of deaths after completion of TB treatment. Previously,
Korenromp et al. [11] showed that across six studies tracing
defaulters and transfers out over a median of one year after start of
treatment, a median of 21% (range 8% to 33%) of the defaulters
and transfers out had died increasing the total percentage of
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that an additional 3.5% should be used to account for the
proportion of overall deaths among TB patients initiating
treatment who defaulted or transferred out. However, the
percentage of defaulters and patients with undocumented
outcomes varies widely between settings [10,97]. An additional
factor may be added for mortality among those people lost to
follow up and might have died because of TB.
The true TB CFR includes the assessment of mortality in not
only diagnosed TB patients undergoing TB treatment, but also in
undiagnosed and consequently untreated TB patients. Our
systematic review did not assess the percentage of deaths among
undiagnosed TB patients, which may constitute a major
contribution to global TB burden.
Generalisability
In our review, we have included both observational and
experimental studies. Differently from the usual high-quality
found in randomised trials, findings of observational studies are
often distorted by confounding and selection bias. Our primary
outcome of interest was mortality due to TB and our search
strategy was specifically set up to answer that question.
Consequently, we were not specifically interested in TB treatment
trials, although our search resulted in four TB treatment trials [88–
91] of which 1 trial reported on mortality among HIV infected due
to TB [90].; two trials on mortality among HIV infected during
TB treatment [88,91] and one trial included HIV uninfected TB
patients [89]. This small number prevented us from conducting
separate analyses for observational and experimental studies.
Studies are often conducted in populations in which the
researchers have a special interest. For example studies on the
cause of death may be conducted in populations with a high death
rate. We have excluded studies among populations that cannot be
considered representative for the general population. If we would
have included studies conducted in populations that are ‘special’,
then the results of our meta-analysis would have been less
generalisable.
The majority of the studies were performed in one district, city,
surrounding or province which may have reduced the represen-
tativeness of the results to the nation. The variation in TB CFR
between studies may have been influenced by unmeasured factors
or may partly be explained by the differences in the data analyses
performed in these studies. The unmeasured factors include, for
example, the quality of the TB program, changes in national
DOTS coverage, treatment regimen, duration of HIV epidemic in
the area, completeness of information on smear and HIV status
and severity of active TB lesions at study entry [47]. In some
prospective studies the data were analyzed as cross–sectional
studies by not taking into consideration the loss to follow up as
they only limited the analyses to the group of people with known
data, in contrast to other studies that either reported that loss to
follow up was either excluded or included in the denominator.
These factors may have influenced the CFR in both directions.
Despite the observed heterogeneity we have chosen to pool the
results of the individual studies. For all analyses we used a random
effect model allowing studies to come from different source
populations with variation in CFR [98]. The overall subgroup
analyses based on HIV and smear status included all more than 10
studies. Excluding the studies with non standardized TB treatment
did not result in different CFR, indicating that the overall results
were robust. To reduce heterogeneity we also presented the results
excluding the studies that only included MDR TB patients as this
largely contributed to heterogeneity. To assess whether the results
in HIV infected persons can be generalized to populations of
varying degrees of HIV-related immunosuppression we were
limited by the fact that the majority of the studies focused on TB
cohorts without providing detailed information on severity of HIV
disease. Those studies reporting on HIV status showed that the
majority of HIV infected TB patients had a similar degree of
immunosuppression as indicated by a CD4 cell count ,200 cells/
mm
3. However from the majority of studies this information is
lacking. To make a strong statement on generalizing our results to
HIV infected populations receiving highly active antiretroviral
therapy (HAART) we again faced the limitation of lack of detailed
information. Use of antiretrovirals was only reported in 16% of the
studies conducted in HIV infected TB cohorts of which only 3
studies where conducted after 1996, the time period when
HAART became available [55,91,99]. Excluding these studies
from the overall analyses in HIV infected persons did not had a
significant effect on the CFR. This may be due to the fact that the
other studies may also have included HIV infected persons
receiving HAART but failed to report this and masking a
difference. Therefore we conclude that the results of this meta-
analysis cannot be applied to populations receiving ART. To date,
WHO has not separated ART cohorts from non ART cohorts,
mostly because the vast majority of TB patients infected with HIV
were not on ART as of 2009 (personal communication).
Previously, we found that in a cohort of people living with HIV
exposed to HAART the presence of TB did not result in an
increased risk of dying compared to those HIV infected persons
not having TB [100]. In this study we were able to pool
multivariate hazard ratio’s of the individual studies, thereby
reducing potential confounding. However in the current meta-
analysis heterogeneity between the studies and the lack of
information on potential confounding factors may have biased
the results. We could not stratify for different age categories but
the majority of cohorts in our meta-analysis included cohorts aged
between 20–40 years which is also the most frequent reported age
group of most reported cases worldwide [1,7]. Therefore we feel
our results are fairly representative regarding age of the most TB
patients.
For several other subgroups we identified only a small number
of studies. It is difficult to draw conclusions among such a limited
number. The pooled results of the subgroup analyses presented in
Table 1 that only include a small number of studies should be
cautiously interpreted until the results of more studies become
available. For example: we found that smear negative TB patients
infected with HIV seemed to have a higher CFR (38%; 95% CI:
23%–53%) than smear positive TB patients infected with HIV
(19%; 95% CI: 15%–23%). Only three studies provided mortality
data in the subgroup of HIV infected smear negative TB patients,
consequently we think it is too early to make a strong statement
that this difference is indeed true.
Assessment of publication bias
We aimed to reduce publication bias by not only identifying
studies in Pubmed and Embase databases but also conducting
reference listing of relevant reviews either found in the search
strategy or known by experts. Limitations of our search strategy
however, included the exclusion of non-English publications and
we did not conduct hand searches of journals as there were not
available to us. As we included observational studies without for
example assessing an effect of an intervention or success of a
diagnostic tool by comparing exposed and non-exposed cohorts,
we cannot state with certainty which direction this would have
influenced our results. In studies assessing an effect, the studies
showing a negative effect may not have been published [101] while
it has also been shown previously that authors were more likely to
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pared to their national language [102]. It may be possible that
studies including a large number of deaths and other negative
outcomes have not been published resulting in a possible
underestimation of TB mortality. Consequently, publication bias
may have influenced the results of our study but this may be
limited especially because our main outcome of interest was
mortality within a TB cohort, which did not include a comparison
with a measure of effect.
Conclusions
In conclusion, despite the limitations as described earlier the
results of this systematic literature review allowed us to quantify
TB CFR in the main overall subgroups defined on HIV status and
smear status. Mortality percentages in HIV infected and HIV
uninfected due to TB and mortality percentages during TB
treatment assessed from this literature review, were used by WHO
to define prior distributions of CFR in countries with vital
registration systems in a Bayesian model that generated posterior
distributions of CFR. The posterior distributions were then used to
predict mortality in countries with no functional vital registration
system. Separate models were used in the group of high–income
countries and in the group of Eastern European countries (where
CFR are higher, partly due to the high burden of MDR–TB)
[103].
Uncertainty still remains significant because we could not
retrieve sufficient data on the following parameters: 1) the
percentage of deaths from TB among TB patients dying during
TB treatment; 2) the percentage of deaths from TB in TB patients
lost to follow up, relapse cases and defaulters; 3) the percentage of
deaths from TB after completion of initial treatment. To obtain
this data, in depth analyses of National Tuberculosis Program data
are needed. Preferably data analyses of those programs where
HIV testing takes place and where adequate follow up and/or
possibility to ascertain data on TB deaths and number of deaths in
defaulters is in place. Furthermore, the use of anti retroviral
therapy should be documented to quantify the CFR in HIV
infected TB patients and the role of ART. For estimation purposes
CFRs need to be adjusted for ART, but this meta-analysis does not
provide data to estimate the adjustment factor. It is important to
improve and validated the measurement of TB mortality.
Operational studies should ensure the quality of data collection,
including collection of information about cause of death and
variables related to this, can often be done more rigidly in a
clinical trial design compared to other study designs. So using the
data of a clinical trial to better evaluate the cause of death in TB
patients can provide good information. Strengthening of TB
surveillance system could include the possibility to discriminate
between deaths due to TB and deaths with TB and follow up of
TB patients even after treatment completion or default. This can
only be established if patients reporting for retreatment are clearly
classified and the new record of the retreatment episode is linked
to previous treatment records. Following these recommendations
the gap in knowledge can be addressed and improving our
understanding of the magnitude and time trends in the burden of
TB disease.
Supporting Information
Table S1 * Unless specified otherwise the mean and range are
presented; 1 Clarification for abbreviations and symbols used
table: TB=tuberculosis, PTB=pulmonary TB; ETB=extra
pulmonary TB; Sm=smear; +=positive; 2=negative; +/2=da-
ta stratified for positive and negative; all=no stratification; n/a:
not applicable because smear diagnostic did not take place;
unk=unknown; HIV=Human Immunodeficiency Virus; 6
Total number of deaths during TB treatment unless specified
otherwise, data in subgroups (e.g. HIV status or smear status) are
used in the specific subgroup analyses; { deaths due to TB; ?loss to
follow up includes not only persons ‘lost to follow up’ but also
‘transfer outs’ and ‘default’ if these numbers are presented because
mortality in these persons is unknown; n.r.: not reported, because
only reporting about people with known outcome, missing data
have already been excluded from the analyses; – Loss to follow up
is unknown and unknown if denominator in–or excludes ltfu;**
Numbers are not excluded from denominator; Follow up period is
either during TB treatment (tbx); expressed in person years (py); or
unknown (unk). 1: HIV testing was accepted by 110 (54%) of 205
patients; 2: These 2 articles refer to the same study but one articles
contributes to information for the primary outcome measure [25]
and the other for the secondary outcome measure [26] 3 Included
the countries Republic of Korea, Peru, China, Russia, Dominican
Republic and Italy; 4 Deaths among people who survived first two
months after initiating TB treatment; 5: We only included the
group of patients with treatment initiated after the war.
(DOC)
Table S2 * MDR=multidrug resistant TB; PTB=pulmonary
TB;
{ TB at least a major contributor to death in HIV– positive
individuals; { Of the 42 patients who died, tuberculosis was listed
on the death certificate as the primary cause of death in 16 (38%),
as a contributing cause of death in 15 (36%), TB was considered a
major contributing cause of death for 4 deaths during the 6–month
treatment period, 16 deaths were considered to be related to TB
because they occurred before the response to anti TB therapy
could be assessed; ** mortality during first 6 months of 12 months
treatment duration;
{{ TB was recorded as immediate cause of
death if death occurred within one month after initiating TB
treatment and there was no other recorded causes. In patients with
multiple cause of death the immediate cause was determined by
review of the clinical data and the establishment of consensus.
{{
Autopsy results were available from 55 of 63 deaths. For 5 of 63
TB deaths HIV status was undocumented while 58 deaths were
HIV-. These 63 TB deaths include 45 smear+ TB deaths.
(DOC)
Table S3 * Categorization subgroups: Human Immunodefi-
ciency Virus positive (HIV pos.) or negative (HIV neg.); Smear
positive (Sm pos.) or negative (Sm neg.); { Unless specified
otherwise follow up time was calculated from the initiation of TB
treatment; 1 Unless specified otherwise, mortality is assessed as
percentage of original TB cohort initiating TB treatment without
adjustment for percentage of patients lost to follow up;
1a 999,7
person years (p.yrs) follow up time for HIV pos. and 560 p.yrs
follow up time for HIV neg.,
1b at 12 months 11.7% loss to follow
up (ltfu);
2a 113,4 p.yrs follow up time for HIV pos. and 123,1 p.yrs
follow up time for HIV neg.,
2b at 12 months 6% ltfu;
3a 19% (33/
174) of HIV pos and 17% (11/65) of HIV neg. was ltfu at end of
treatment,
3b 25% (44/174) of HIV pos. and 26% (17/65) of HIV
neg. was lftu at the end of follow up period;
4 HIV status was
available for 96% (793/827) registered TB patients, 11.9% (99/
827) registered TB patients was ltfu on 32 months and 18% (152/
827) registered TB patients was ltfu at 7 years;
5a at end of 6
months treatment regimen 6.1% (22/359) defaulted, was ltfu or
transferred out, and 12% (42/359) was ltfu at end of 2 years follow
up,
5b at end of 12 months treatment regimen 21% (63/304)
defaulted, was ltfu or transferred out, and 20% (61/304) was ltfu at
end of 2 years follow up;
6 at end of treatment 5% (195 of 3,600
patients starting TB treatment) could not be followed up because
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excluded from the denominator in all analyses;
7 at the end of
treatment 13% (68/512) was loss to follow up and these were
excluded from the denominator in all analyses;
8a at end of
treatment records were unavailable for 12% (20/170) HIV pos.
and 16% (96/597) HIV neg.,
8b 39% (67/170) of initial cohort was
followed up in HIV pos. and 43% (258/597) in HIV neg.;
9 at end
of treatment 2% (25/1,171) was ltfu, 46 could not be traced during
follow up consequently a total of 6% (71/1,171) was ltfu at end of
the study;
10 ltfu excluded from the denominator in the treatment
outcome analyses;
11 at end of treatment 12% (70/561) was ltfu;
12a ltfu excluded from the denominator in the treatment outcome
analyses,
12b follow up was only possible for 60% (162/271) of
initial cohort.
(DOC)
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